加载中
NASDAQHealthcareBiotechnology
最新数据
US$15.30
−US$0.01 · -0.07%
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
常规交易时段
US$15.30
−US$0.01 · -0.07%
盘中时间采用ET。市场数据可能有所延迟。
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
日内区间
当前US$15.30
52周区间
当前US$15.30
盘中时间采用ET。市场数据可能有所延迟。
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
日内区间
当前US$15.30
52周区间
当前US$15.30
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.58亿 CNY | 9.81亿 CNY | 2.22亿 CNY | 2.1亿 CNY | 2791万 CNY |
| 销货成本 | 1.32亿 CNY | 2908.5万 CNY | 3054.3万 CNY | 2199.8万 CNY | 332.8万 CNY |
| 毛利 | 4.27亿 CNY | 9.52亿 CNY | 1.91亿 CNY | 1.88亿 CNY | 2458.2万 CNY |
| 研究与开发 | 10.83亿 CNY | 9.47亿 CNY | 7.07亿 CNY | 7.43亿 CNY | 7.66亿 CNY |
| 销售、一般及管理费用 | 5.23亿 CNY | 3.83亿 CNY | 3.76亿 CNY | 3.28亿 CNY | 1.91亿 CNY |
| 营业费用 | 16.06亿 CNY | 13.21亿 CNY | 10.64亿 CNY | 10.38亿 CNY | 9.58亿 CNY |
| 利息收入 | 7988.75万 CNY | 3784万 CNY | 3240.9万 CNY | 972.7万 CNY | 710.6万 CNY |
| 利息支出 | 5259.69万 CNY | 6445.5万 CNY | 9605.7万 CNY | 5278.5万 CNY | 1673.1万 CNY |
| 折旧和摊销 | 8648万 CNY | 9316.9万 CNY | 9319.5万 CNY | 6291.5万 CNY | 2832.6万 CNY |
| 营业利润 | −11.79亿 CNY | −3.7亿 CNY | −8.73亿 CNY | −8.5亿 CNY | −8.7亿 CNY |
| 净利润 | −12.09亿 CNY | −4.05亿 CNY | −9.26亿 CNY | −8.83亿 CNY | −7.82亿 CNY |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
